title: Placebo-controlled, double-blind study of the efficacy and safety of triamcinolone acetonide aerosol nasal inhaler in pediatric patients with seasonal allergic rhinitis.
abstract: Triamcinolone acetonide (TAA) aerosol nasal inhaler has been shown to effectively relieve the symptoms of seasonal allergic rhinitis in adults and adolescents. We conducted a study to evaluate the efficacy and safety of once-daily administration of TAA aerosol nasal inhaler in pediatric patients aged 6 to 11 years with grass seasonal allergic rhinitis. This multicenter, randomized, double-blind, placebo-controlled, parallel-group study enrolled 116 children who were treated with either TAA aerosol nasal inhaler (220 micrograms/d) or placebo once daily for 2 weeks. Patients evaluated the severity of rhinitis symptoms (nasal stuffiness, discharge, sneezing, and itching) daily according to a four-point scale (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). Patients' and physicians' global evaluations of overall treatment efficacy were assessed at the end of the 2-week treatment period. Patients treated with TAA aerosol nasal inhaler had significantly greater reductions in all nasal symptom scores overall and in virtually all symptoms at the end of week 1 and week 2 compared with those in the placebo group. Both patients' and physicians' global evaluations of efficacy favored TAA aerosol nasal inhaler over placebo. This study demonstrated that once-daily administration of 220 micrograms of TAA aerosol nasal inhaler was well tolerated and effectively reduced the symptoms of seasonal allergic rhinitis in pediatric patients.
authors: Allergy & Asthma Centers of Charleston, South Carolina, USA.
authors: C H
authors: CH
authors: Banov
authors: W S
authors: WS
authors: Silvers
authors: A W
authors: AW
authors: Green
authors: J H
authors: JH
authors: van Bavel
authors: J A
authors: JA
authors: Winder
authors: G
authors: G
authors: Feiss
authors: B
authors: B
authors: Simpson
authors: J A
authors: JA
authors: Furst
authors: J A
authors: JA
authors: Smith
mesh_terms: D000281:Administration, Intranasal; D000336:Aerosols; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D012621:Seasons; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000336:Aerosols; D000893:Anti-Inflammatory Agents; D014222:Triamcinolone Acetonide